GB Sciences, Inc. (OTCQB: GBLX) declared filing the second in a series of patent applications for life science inventions by its wholly-owned partner, Growblox Life Sciences, LLC.

Inflammatory disorders represent a serious health and economic burden in the US with over $200 billion spent annually. GB Sciences’ novel cannabis-based therapies could significantly assist both patients and society. According to the CDC, arthritis affects 22.7% (52.5 million) of adults in the US (2010-2012), and the prevalence is projected to increase to an estimated 26% (78 million of the projected total adult population) by 2040. The total costs associated with arthritis were $128 billion in 2003, and they have been increasing over time. In Addition To, 8.6% (7 million) children and 7.4% (17.8 million) adults had asthma (2014), which costs the US $56 billion per year. Inflammatory Bowel Disease (“IBD”), which includes Crohn’s disease and ulcerative colitis) affected between 1 and 1.3 million people in the US (2007). Per the CDC, IBD is an expensive, chronic disease, which cost the US $11.8 billion in 2008, despite the lower prevalence rates.

The current provisional patent application covers cannabinoid-containing complex mixtures (“CCCM”) capable of preventing and treating a spectrum of inflammatory disorders. The application focuses on the use of CCCM to disrupt the signaling pathways in certain immune cells that lead to the initiation and maintenance of inflammatory responses. Both common and uncommon inflammatory disorders, ranging from chronic arthritis to acute responses to insect stings, are likely to be effectively targeted by this therapeutic approach.

“Although inflammatory reactions are a necessary part of human immunity in some situations (e.g., fighting pathogens), humans (and animals) suffer from multiple inflammatory disorders involving “hyper-inflammatory” responses. Our novel CCCM plannedally target multiple arms of these hyper-inflammatory responses in parallel for maximal effect, rather than inhibiting a single arm like other commonly available anti-inflammatory therapies,” explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. “For example, anti-histamines are partly effective, but leave untouched those inflammatory pathways that lead to release of other pro-inflammatory mediators, such as bioactive lipids and cytokines. GB Sciences’ approach is to simultaneously target as many inflammatory outputs as possible with our CCCM, leading to more comprehensive relief from tissue inflammation.”

John Poss, CEO, GB Sciences states: GB Sciences is committed to developing cannabis-based therapies for inflammatory disorders that affect large numbers of patients (arthritis, dermatitis, allergic asthma, eczema, IBD, Crohn’s disease, etc.). Our CCCM products will be developed to the same efficacy and safety standards as other commercially available anti-inflammatory therapies; however, cannabis-based medicines often have more favorable side effect profiles than traditional pharmaceuticals.”


Please enter your comment!
Please enter your name here